TitleAssistant Professor
InstitutionBaylor College of Medicine
DepartmentDepartment of Medicine
Address1102 BATES
Houston, TX 77030
vCardDownload vCard
    Other Positions
    TitleAssistant Professor
    InstitutionBaylor College of Medicine
    DepartmentBreast Center
    DivisionBreast Cancer Center

    TitleAssistant Professor
    InstitutionBaylor College of Medicine
    DepartmentCenter for Cell & Gene Therapy
    DivisionCenter for Cell & Gene Therapy

    TitleAssistant Professor
    InstitutionBaylor College of Medicine
    DepartmentDuncan Cancer Center
    DivisionCancer Center

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Savage SR, Yi X, Lei JT, Wen B, Zhao H, Liao Y, Jaehnig EJ, Somes LK, Shafer PW, Lee TD, Fu Z, Dou Y, Shi Z, Gao D, Hoyos V, Gao Q, Zhang B. Pan-cancer proteogenomics expands the landscape of therapeutic targets. Cell. 2024 Jun 17. PMID: 38917788.
      Citations:    Fields:    
    2. Leung WK, Torres Chavez AG, French-Kim M, Shafer P, Mamonkin M, Hill LC, Kuvalekar M, Velazquez Y, Watanabe A, Watanabe N, Hoyos V, Lulla PD, Leen AM, Leung WK, Torres Chavez AG, French-Kim M, Shafer P, Mamonkin M, Hill LC, Kuvalekar M, Velazquez Y, Watanabe A, Watanabe N, Hoyos V, Lulla P, Leen AM. Targeting IDH2R140Q and other neoantigens in acute myeloid leukemia. Blood. 2024 Apr 25; 143(17):1726-1737. PMID: 38241630; PMCID: PMC11103096.
      Citations:    Fields:    
    3. Shafer P, Leung WK, Woods M, Choi JM, Rodriguez-Plata CM, Maknojia A, Mosquera A, Somes LK, Joubert J, Manliguez A, Ranjan R, Burt B, Lee HS, Zhang B, Fuqua S, Rooney C, Leen AM, Hoyos V. Incongruity between T cell receptor recognition of breast cancer hotspot mutations ESR1 Y537S and D538G following exogenous peptide loading versus endogenous antigen processing. Cytotherapy. 2024 03; 26(3):266-275. PMID: 38231165; PMCID: PMC10922969.
      Citations:    Fields:    Translation:Humans
    4. Chamorro DF, Somes LK, Hoyos V. Engineered Adoptive T-Cell Therapies for Breast Cancer: Current Progress, Challenges, and Potential. Cancers (Basel). 2023 Dec 26; 16(1). PMID: 38201551; PMCID: PMC10778447.
    5. Hoyos V, Vasileiou S, Kuvalekar M, Watanabe A, Tzannou I, Velazquez Y, French-Kim M, Leung W, Lulla S, Robertson C, Foreman C, Wang T, Bulsara S, Lapteva N, Grilley B, Ellis M, Osborne CK, Coscio A, Nangia J, Heslop HE, Rooney CM, Vera JF, Lulla P, Rimawi M, Leen AM. Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer. Ther Adv Med Oncol. 2022; 14:17588359221107113. PMID: 35860837; PMCID: PMC9290161.
    6. Shafer P, Kelly LM, Hoyos V. Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects. Front Immunol. 2022; 13:835762. PMID: 35309357; PMCID: PMC8928448.
      Citations:    Fields:    Translation:HumansCells
    7. Chen N, Higashiyama N, Hoyos V. Predictive Biomarkers of Immune Checkpoint Inhibitor Response in Breast Cancer: Looking beyond Tumoral PD-L1. Biomedicines. 2021 Dec 08; 9(12). PMID: 34944679; PMCID: PMC8698415.
      Citations: 1     
    8. Nalawade SA, Shafer P, Bajgain P, McKenna MK, Ali A, Kelly L, Joubert J, Gottschalk S, Watanabe N, Leen A, Parihar R, Vera Valdes JF, Hoyos V. Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer. J Immunother Cancer. 2021 11; 9(11). PMID: 34815355; PMCID: PMC8611441.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    9. McKenna MK, Englisch A, Brenner B, Smith T, Hoyos V, Suzuki M, Brenner MK. Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity. Mol Ther. 2021 Dec 01; 29(12):3529-3533. PMID: 34706248; PMCID: PMC8636171.
      Citations: 1     Fields:    
    10. Mouabbi JA, Chand M, Asghar IA, Sakhi R, Ockner D, Dul CL, Hadid T, Aref A, Rimawi MF, Hoyos V. Lumpectomy followed by radiation improves survival in HER2 positive and triple-negative breast cancer with high tumor-infiltrating lymphocytes compared to mastectomy alone. Cancer Med. 2021 07; 10(14):4790-4795. PMID: 34080777; PMCID: PMC8290225.
      Citations: 2     Fields:    Translation:HumansCells
    11. Ferrari F, Salviato E, Brenner MK, Gottschalk S, Hoyos V, Arnone CM, Polito VA, Mastronuzzi A, Carai A, Diomedi FC, Antonucci L, Petrilli LL, Vinci M, Scarsella M, De Stefanis C, Weber G, Quintarelli C, De Angelis B, Locatelli F, Caruana I, Del Bufalo F. Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas. J Immunother Cancer. 2021 05; 9(5). PMID: 33963009; PMCID: PMC8108682.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    12. McKenna MK, Englisch A, Brenner B, Smith T, Hoyos V, Suzuki M, Brenner MK. Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity. Mol Ther. 2021 05 05; 29(5):1808-1820. PMID: 33571680; PMCID: PMC8116608.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    13. Higashiyama N, Nangia J, Shafaee MN, Chen N, Michael BL, Rimawi M, Hoyos V. Dose-reduced trastuzumab deruxtecan can be safely used in liver failure and active leptomeningeal metastases. Curr Probl Cancer Case Rep. 2020 Dec 15; 2. PMID: 34505091; PMCID: PMC8425325.
    14. Bajgain P, Tawinwung S, D'Elia L, Sukumaran S, Watanabe N, Hoyos V, Lulla P, Brenner MK, Leen AM, Vera JF. CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation. J Immunother Cancer. 2018 05 10; 6(1):34. PMID: 29747685; PMCID: PMC5944113.
      Citations: 39     Fields:    Translation:Humans
    15. Hoyos V, Borrello I. The immunotherapy era of myeloma: monoclonal antibodies, vaccines, and adoptive T-cell therapies. Blood. 2016 09 29; 128(13):1679-87. PMID: 27506540.
      Citations: 24     Fields:    Translation:HumansCells
    16. Yagyu S, Hoyos V, Brenner MK, Del Bufalo F. Multiple mechanisms determine the sensitivity of human-induced pluripotent stem cells to the inducible caspase-9 safety switch. Mol Ther Methods Clin Dev. 2016; 3:16003. PMID: 27626039; PMCID: PMC5008202.
      Citations: 8     
    17. Manzo T, Hoyos V, Yagyu S, Jacot J, Benavides O, Rosen D, Brenner MK, Del Bufalo F, Caruana I. 3D modeling of human cancer: A PEG-fibrin hydrogel system to study the role of tumor microenvironment and recapitulate the in vivo effect of oncolytic adenovirus. Biomaterials. 2016 Apr; 84:76-85. PMID: 26826297.
      Citations: 25     Fields:    Translation:HumansAnimalsCells
    18. Hoyos V, Del Bufalo F, Yagyu S, Ando M, Dotti G, Suzuki M, Bouchier-Hayes L, Alemany R, Brenner MK. Mesenchymal Stromal Cells for Linked Delivery of Oncolytic and Apoptotic Adenoviruses to Non-small-cell Lung Cancers. Mol Ther. 2015 Sep; 23(9):1497-506. PMID: 26084970; PMCID: PMC4817892.
      Citations: 14     Fields:    Translation:HumansAnimalsCells
    19. Yagyu S, Hoyos V, Del Bufalo F, Brenner MK. An Inducible Caspase-9 Suicide Gene to Improve the Safety of Therapy Using Human Induced Pluripotent Stem Cells. Mol Ther. 2015 Sep; 23(9):1475-85. PMID: 26022733; PMCID: PMC4817893.
      Citations: 48     Fields:    Translation:HumansAnimalsCells
    20. Caruana I, Savoldo B, Hoyos V, Weber G, Liu H, Kim ES, Ittmann MM, Marchetti D, Dotti G. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat Med. 2015 May; 21(5):524-9. PMID: 25849134; PMCID: PMC4425589.
      Citations: 251     Fields:    Translation:HumansAnimalsCells
    21. Ando M, Hoyos V, Yagyu S, Tao W, Ramos CA, Dotti G, Brenner MK, Bouchier-Hayes L. Bortezomib sensitizes non-small cell lung cancer to mesenchymal stromal cell-delivered inducible caspase-9-mediated cytotoxicity. Cancer Gene Ther. 2014 Nov; 21(11):472-482. PMID: 25323693; PMCID: PMC4245333.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    22. Nishio N, Diaconu I, Liu H, Cerullo V, Caruana I, Hoyos V, Bouchier-Hayes L, Savoldo B, Dotti G. Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors. Cancer Res. 2014 Sep 15; 74(18):5195-205. PMID: 25060519; PMCID: PMC4167556.
      Citations: 128     Fields:    Translation:AnimalsCells
    23. Geldres C, Savoldo B, Hoyos V, Caruana I, Zhang M, Yvon E, Del Vecchio M, Creighton CJ, Ittmann M, Ferrone S, Dotti G. T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo. Clin Cancer Res. 2014 Feb 15; 20(4):962-71. PMID: 24334762; PMCID: PMC3944408.
      Citations: 36     Fields:    Translation:HumansAnimalsCells
    24. Hoyos V, Savoldo B, Dotti G. Genetic modification of human T lymphocytes for the treatment of hematologic malignancies. Haematologica. 2012 Nov; 97(11):1622-31. PMID: 22929977; PMCID: PMC3487433.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    25. Giordano Attianese GM, Marin V, Hoyos V, Savoldo B, Pizzitola I, Tettamanti S, Agostoni V, Parma M, Ponzoni M, Bertilaccio MT, Ghia P, Biondi A, Dotti G, Biagi E. In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor. Blood. 2011 May 05; 117(18):4736-45. PMID: 21406718; PMCID: PMC3100686.
      Citations: 36     Fields:    Translation:HumansAnimalsCells
    26. Quintarelli C, Dotti G, Hasan ST, De Angelis B, Hoyos V, Errichiello S, Mims M, Luciano L, Shafer J, Leen AM, Heslop HE, Rooney CM, Pane F, Brenner MK, Savoldo B. High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells. Blood. 2011 Mar 24; 117(12):3353-62. PMID: 21278353; PMCID: PMC3069675.
      Citations: 42     Fields:    Translation:HumansCells
    27. Yvon E, Del Vecchio M, Savoldo B, Hoyos V, Anichini A, Dotti G, Brenner MK, Dutour A. Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells. Clin Cancer Res. 2009 Sep 15; 15(18):5852-60. PMID: 19737958; PMCID: PMC2745508.
      Citations: 65     Fields:    Translation:HumansAnimalsCells
    28. Vera JF, Hoyos V, Savoldo B, Quintarelli C, Giordano Attianese GM, Leen AM, Liu H, Foster AE, Heslop HE, Rooney CM, Brenner MK, Dotti G. Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. Mol Ther. 2009 May; 17(5):880-8. PMID: 19259067; PMCID: PMC2835146.
      Citations: 56     Fields:    Translation:HumansAnimalsCells
    29. Quintarelli C, Dotti G, De Angelis B, Hoyos V, Mims M, Luciano L, Heslop HE, Rooney CM, Pane F, Savoldo B. Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia. Blood. 2008 Sep 01; 112(5):1876-85. PMID: 18591381; PMCID: PMC3401035.
      Citations: 50     Fields:    Translation:HumansCells
    HOYOS's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (173)
    Co-Authors (32)
    Similar People (60)
    Same Department Expand Description